The first patient has been dosed in a China-based Phase 3 clinical trial evaluating I-Mab’s (NASDAQ:IMAB)
human CD38 antibody TJ202/MOR202, combined with Celgene’s Revlimid
(lenalidomide) and dexamethasone, in patients with relapsed/refractory
multiple myeloma.
IMAB in-licensed exclusive rights to the candidate in mainland China, Taiwan, Hong Kong and Macao from MorphoSys (NASDAQ:MOR).
https://seekingalpha.com/news/3564992-late-stage-study-underway-for-i-mab-candidate-in-multiple-myeloma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.